Global Licensing Momentum Polpharma Biologics has active licensing and distribution deals across multiple regions, including Argentina with Tuteur Group, Brazil with Libbs, the MENA region with MS Pharma Group, France for Ranivisio via Bioeq Teva arrangements, and a U.S. launch with Sandoz. This track record signals growing appetite for regional commercialization partnerships and exclusive rights, presenting opportunities to pursue additional licensing deals in high potential markets and expand geographic reach through partner networks.

Integrated CDMO Polpharma Biologics delivers end to end biosimilar development and manufacturing from cell line to finished product, including regulatory strategy and quality integration, leveraging trusted CDMOs. This makes them a strong partner for third party biosimilar developers seeking development, tech transfer and scale up services, opening revenue streams from development fees, manufacturing capacity and ongoing supply contracts.

Pipeline Momentum With Tyruko launched in the U.S. and Ranivisio launched in France, plus Vedolizumab license activity, the company shows near term revenue catalysts across neuroimmunology and ophthalmology. Sales opportunities exist to license additional assets, co market, or enter value based partnerships with payers and healthcare systems to accelerate uptake in priority indications.

Regional Market Access Active regional licensing activity demonstrates readiness to tailor market access, pricing and payer strategies. This creates opportunities to enter new regions such as APAC and Europe with locally adapted deals, leveraging partner expertise to navigate regulatory and reimbursement landscapes and maximize patient access.

Strategic Partnerships The history of collaborations with Sandoz, Fresenius Kabi, Libbs, MS Pharma Group and ProBioGen indicates a proven model for co development, licensing and distribution. This can be leveraged to approach new partners for co development, exclusive distribution, or capacity sharing agreements to accelerate growth and diversify revenue streams.